Pages with the fewest revisions

Jump to navigation Jump to search

Showing below up to 250 results in range #301 to #550.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

  1. Life Span Study‏‎ (1 revision)
  2. Thoracic airways‏‎ (1 revision)
  3. ICRP Publication 108‏‎ (1 revision)
  4. Brachytherapy‏‎ (1 revision)
  5. Multifactorial diseases‏‎ (1 revision)
  6. ICRP Publication 121‏‎ (1 revision)
  7. Case–control study‏‎ (1 revision)
  8. Nominal value‏‎ (1 revision)
  9. ICRP Publication 136‏‎ (1 revision)
  10. Collective dose‏‎ (1 revision)
  11. ICRP Publication 150‏‎ (1 revision)
  12. ICRP Publication 25‏‎ (1 revision)
  13. ICRP Publication 31‏‎ (1 revision)
  14. Deterministic effect‏‎ (1 revision)
  15. ICRP Publication 46‏‎ (1 revision)
  16. ICRP Publication 61‏‎ (1 revision)
  17. Radon progeny‏‎ (1 revision)
  18. ICRP Publication 76‏‎ (1 revision)
  19. Reference parameter value‏‎ (1 revision)
  20. Equilibrium equivalent concentration‏‎ (1 revision)
  21. Expanded radiation field‏‎ (1 revision)
  22. 1937 Recommendations‏‎ (1 revision)
  23. Adventitious source‏‎ (1 revision)
  24. Annual intake‏‎ (1 revision)
  25. Supervised area‏‎ (1 revision)
  26. Thoron progeny‏‎ (1 revision)
  27. ICRP Publication 109‏‎ (1 revision)
  28. Transgenerational effect‏‎ (1 revision)
  29. ICRP Publication 122‏‎ (1 revision)
  30. Non-homologous end joining‏‎ (1 revision)
  31. ICRP Publication 137‏‎ (1 revision)
  32. Optimisation of protection‏‎ (1 revision)
  33. ICRP Publication 151‏‎ (1 revision)
  34. ICRP Publication 26‏‎ (1 revision)
  35. DS86‏‎ (1 revision)
  36. ICRP Publication 32‏‎ (1 revision)
  37. Quasi-threshold dose‏‎ (1 revision)
  38. ICRP Publication 47‏‎ (1 revision)
  39. ICRP Publication 62‏‎ (1 revision)
  40. Ras‏‎ (1 revision)
  41. ICRP Publication 77‏‎ (1 revision)
  42. Reference phantom‏‎ (1 revision)
  43. Equilibrium factor‏‎ (1 revision)
  44. ICRP Publication 90‏‎ (1 revision)
  45. 1950 Recommendations‏‎ (1 revision)
  46. Size-specific dose estimate‏‎ (1 revision)
  47. Specific absorbed fraction‏‎ (1 revision)
  48. Surface contamination‏‎ (1 revision)
  49. Backscatter factor‏‎ (1 revision)
  50. ICRP Publication 10A‏‎ (1 revision)
  51. Translocation‏‎ (1 revision)
  52. Multistage carcinogenesis model‏‎ (1 revision)
  53. ICRP Publication 123‏‎ (1 revision)
  54. Charged-particle equilibrium‏‎ (1 revision)
  55. ICRP Publication 138‏‎ (1 revision)
  56. Collimation‏‎ (1 revision)
  57. ICRP Publication 152‏‎ (1 revision)
  58. Phantom‏‎ (1 revision)
  59. ICRP Publication 27‏‎ (1 revision)
  60. ICRP Publication 33‏‎ (1 revision)
  61. Detriment-adjusted risk‏‎ (1 revision)
  62. ICRP Publication 48‏‎ (1 revision)
  63. Dose-response function‏‎ (1 revision)
  64. ICRP Publication 63‏‎ (1 revision)
  65. Rb‏‎ (1 revision)
  66. ICRP Publication 78‏‎ (1 revision)
  67. Elemental dose‏‎ (1 revision)
  68. Reference value‏‎ (1 revision)
  69. ICRP Publication 91‏‎ (1 revision)
  70. Exposed individuals‏‎ (1 revision)
  71. 1954 Recommendations‏‎ (1 revision)
  72. Slice‏‎ (1 revision)
  73. Apoptosis‏‎ (1 revision)
  74. Threshold level‏‎ (1 revision)
  75. ICRP Publication 11‏‎ (1 revision)
  76. ICRP Publication 124‏‎ (1 revision)
  77. ICRP Publication 139‏‎ (1 revision)
  78. Organ at risk‏‎ (1 revision)
  79. ICRP Publication 153‏‎ (1 revision)
  80. ICRP Publication 28‏‎ (1 revision)
  81. Principles of protection‏‎ (1 revision)
  82. ICRP Publication 34‏‎ (1 revision)
  83. Radiation-induced second cancer‏‎ (1 revision)
  84. ICRP Publication 49‏‎ (1 revision)
  85. Dose per unit intake coefficient‏‎ (2 revisions)
  86. Emergency‏‎ (2 revisions)
  87. Reproductive integrity‏‎ (2 revisions)
  88. Exposure, external or internal‏‎ (2 revisions)
  89. Safety case‏‎ (2 revisions)
  90. Slow repair‏‎ (2 revisions)
  91. Graft vs host disease‏‎ (2 revisions)
  92. Air-kerma, incident‏‎ (2 revisions)
  93. Isotropic geometry‏‎ (2 revisions)
  94. Heliosphere‏‎ (2 revisions)
  95. Lineal energy‏‎ (2 revisions)
  96. Thyroid blocking‏‎ (2 revisions)
  97. Transparency‏‎ (2 revisions)
  98. Class SR-0 gases‏‎ (2 revisions)
  99. Waste disposal‏‎ (2 revisions)
  100. Non-targeted effects‏‎ (2 revisions)
  101. Decontamination‏‎ (2 revisions)
  102. Procedural values‏‎ (2 revisions)
  103. Diastasis‏‎ (2 revisions)
  104. Dose rate‏‎ (2 revisions)
  105. Reasonableness‏‎ (2 revisions)
  106. Emergency exposure situation‏‎ (2 revisions)
  107. Erythropoietin‏‎ (2 revisions)
  108. Residual dose‏‎ (2 revisions)
  109. Exposure (in the context of inhalation)‏‎ (2 revisions)
  110. Safety culture‏‎ (2 revisions)
  111. Fractionation and dose delivery patterns‏‎ (2 revisions)
  112. Solar cosmic radiation‏‎ (2 revisions)
  113. Inhalability‏‎ (2 revisions)
  114. Spontaneous fission‏‎ (2 revisions)
  115. Itinerant (radiation) worker‏‎ (2 revisions)
  116. Linear-non-threshold model‏‎ (2 revisions)
  117. Broad beam therapy irradiation technique‏‎ (2 revisions)
  118. Trapped particles‏‎ (2 revisions)
  119. Class SR-1 gases‏‎ (2 revisions)
  120. Committed effective dose‏‎ (2 revisions)
  121. Orphan source‏‎ (2 revisions)
  122. Cost-benefit analysis‏‎ (2 revisions)
  123. Planned exposure situation‏‎ (2 revisions)
  124. Decontamination factor‏‎ (2 revisions)
  125. Progenitor cell‏‎ (2 revisions)
  126. Radiation belt‏‎ (2 revisions - redirect page)
  127. Radiological protection principles‏‎ (2 revisions)
  128. Dose rate effectiveness factor‏‎ (2 revisions)
  129. Emergency plan‏‎ (2 revisions)
  130. Ethics‏‎ (2 revisions)
  131. Respiratory protection‏‎ (2 revisions)
  132. ALARA‏‎ (2 revisions)
  133. Scintigraphy‏‎ (2 revisions)
  134. Solar cycle‏‎ (2 revisions)
  135. Inner bremsstrahlung‏‎ (2 revisions)
  136. Hierarchical tissues‏‎ (2 revisions)
  137. Area monitoring‏‎ (2 revisions)
  138. Systemic model‏‎ (2 revisions)
  139. Linear-quadratic dose response model‏‎ (2 revisions)
  140. Benthic‏‎ (2 revisions)
  141. Time factor‏‎ (2 revisions)
  142. Bronchial region‏‎ (2 revisions)
  143. Myocardial perfusion‏‎ (2 revisions)
  144. Class SR-2 gases‏‎ (2 revisions)
  145. What is Radon?‏‎ (2 revisions)
  146. Committed equivalent dose‏‎ (2 revisions)
  147. Platelet-derived growth factor‏‎ (2 revisions)
  148. Dichotomous‏‎ (2 revisions)
  149. Radiation modifier‏‎ (2 revisions)
  150. Radionuclides of natural origin‏‎ (2 revisions)
  151. Recovery (cellular or tissue)‏‎ (2 revisions)
  152. Retrievability‏‎ (2 revisions)
  153. Immune system‏‎ (2 revisions)
  154. Activity‏‎ (2 revisions)
  155. Institutional control‏‎ (2 revisions)
  156. Stakeholder‏‎ (2 revisions)
  157. High level waste‏‎ (2 revisions)
  158. Tachycardia‏‎ (2 revisions)
  159. Tissue equivalent material‏‎ (2 revisions)
  160. Myocardial stress test‏‎ (2 revisions)
  161. Clearance‏‎ (2 revisions)
  162. Oversight‏‎ (2 revisions)
  163. Deontological Ethics‏‎ (2 revisions)
  164. Projected dose‏‎ (2 revisions)
  165. Differentiation‏‎ (2 revisions)
  166. Dose constraint‏‎ (2 revisions)
  167. Radioresponsiveness‏‎ (2 revisions)
  168. Early normal tissue responses‏‎ (2 revisions)
  169. Recovery responder‏‎ (2 revisions)
  170. Reversibility‏‎ (2 revisions)
  171. In vivo radiobioassay‏‎ (2 revisions)
  172. Solar particle event‏‎ (2 revisions)
  173. Beta-minus decay‏‎ (2 revisions)
  174. Clearance level‏‎ (2 revisions)
  175. Worker‏‎ (2 revisions)
  176. Nuclear track detectors‏‎ (2 revisions)
  177. Radiation safety officer‏‎ (2 revisions)
  178. Dose conversion coefficient‏‎ (2 revisions)
  179. Radiosensitiser‏‎ (2 revisions)
  180. Edema‏‎ (2 revisions)
  181. Rehabilitation of living conditions‏‎ (2 revisions)
  182. Excess relative risk‏‎ (2 revisions)
  183. Right to know‏‎ (2 revisions)
  184. Exposure situation‏‎ (2 revisions)
  185. Incidence‏‎ (2 revisions)
  186. Solar wind‏‎ (2 revisions)
  187. Growth factor‏‎ (2 revisions)
  188. Alimentary tract transfer factor‏‎ (2 revisions)
  189. Target tissue‏‎ (2 revisions)
  190. Beta-plus decay‏‎ (2 revisions)
  191. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  192. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  193. Working level‏‎ (2 revisions)
  194. OLINDA/EXM‏‎ (2 revisions)
  195. Particle radiance‏‎ (2 revisions)
  196. Cumulative dose‏‎ (2 revisions)
  197. Protection strategy‏‎ (2 revisions)
  198. Radiation source‏‎ (2 revisions)
  199. Radiosensitivity, cellular‏‎ (2 revisions)
  200. Effect Dose 50‏‎ (2 revisions)
  201. Endogeneous excretion‏‎ (2 revisions)
  202. Rigidity‏‎ (2 revisions)
  203. Exposure to Radon at Home‏‎ (2 revisions)
  204. Security‏‎ (2 revisions)
  205. Incident‏‎ (2 revisions)
  206. GATA binding protein 2‏‎ (2 revisions)
  207. Intermediate level waste‏‎ (2 revisions)
  208. Stenosis‏‎ (2 revisions)
  209. Hormones‏‎ (2 revisions)
  210. Authorization‏‎ (2 revisions)
  211. Local DRL‏‎ (2 revisions)
  212. Tolerability‏‎ (2 revisions)
  213. Medical exposure‏‎ (2 revisions)
  214. Naturally occurring radioactive material‏‎ (2 revisions)
  215. Clonogenic cells‏‎ (2 revisions)
  216. Working level month‏‎ (2 revisions)
  217. Curie‏‎ (2 revisions)
  218. Inclusiveness‏‎ (2 revisions)
  219. Acute radiation syndrome‏‎ (2 revisions)
  220. Source-related‏‎ (2 revisions)
  221. Internal conversion electron‏‎ (2 revisions)
  222. LD 50/30‏‎ (2 revisions)
  223. Hounsfield unit‏‎ (2 revisions)
  224. Authorized limit‏‎ (2 revisions)
  225. Telangiectasia‏‎ (2 revisions)
  226. Member of the public‏‎ (2 revisions)
  227. Cardiac arrhythmias‏‎ (2 revisions)
  228. Unattached fraction‏‎ (2 revisions)
  229. Necrosis‏‎ (2 revisions)
  230. Clonogenic survival‏‎ (2 revisions)
  231. Patient entrance reference point‏‎ (2 revisions)
  232. Cytokines‏‎ (2 revisions)
  233. Potential recoverability correction factor‏‎ (2 revisions)
  234. Protective action guide‏‎ (2 revisions)
  235. Radiation worker‏‎ (2 revisions)
  236. Dose criteria‏‎ (2 revisions)
  237. Radon: Units of Measure‏‎ (2 revisions)
  238. Reference air kerma‏‎ (2 revisions)
  239. Environmental exposure‏‎ (2 revisions)
  240. Exempt waste‏‎ (2 revisions)
  241. Self-help protection‏‎ (2 revisions)
  242. Individual-related‏‎ (2 revisions)
  243. Adaptive response‏‎ (2 revisions)
  244. Alveolar-interstitial region‏‎ (2 revisions)
  245. Storage‏‎ (2 revisions)
  246. Autoimmune disease‏‎ (2 revisions)
  247. Track structure‏‎ (2 revisions)
  248. Mendelian diseases‏‎ (2 revisions)
  249. ICRP Publication 118‏‎ (2 revisions)
  250. Cardiac valve diseases‏‎ (2 revisions)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)